CliffBio
small molecule

SOLOSEC

SECNIDAZOLE

Loss of exclusivityDecember 2041latest FDA-listed patent expiry
CompanyEvofem Biosciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameSOLOSEC
Active ingredientSECNIDAZOLE
Strength2GM/PACKET
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusRX

Listed patents

PatentExpiresType
12280037December 2041use U-3302
11684607September 2035product
11020377September 2035product
11000508September 2035product
10682338September 2035product
10849884September 2035product
10857133September 2035product
11602522September 2035product
10335390September 2035product
11324721September 2035product
11000507September 2035product

Regulatory exclusivity

CodeExpires
GAINSeptember 2027
NCESeptember 2022

More from Evofem Biosciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.